Correspondence 0001731122-25-000110 from Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Date: Jan. 22, 2025 · CIK: 0001708331 · Accession: 0001731122-25-000110
AI Filing Summary & Sentiment
File numbers found in text: 333-284089
Letter
Re: Virpax Pharmaceuticals, Inc.
January 22, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form S-1, as amended
File No. 333-284089
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Requested Date: Monday, January 27, 2025
Requested Time: 5:00 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, the undersigned, as the sole placement agent for the proposed public offering on a best efforts basis of securities of Virpax Pharmaceuticals, Inc. (the “Company”), hereby join the Company’s request that the effective date of the above-referenced registration statement on Form S-1, as amended, be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on Monday, January 27, 2025, or as soon thereafter as possible.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
SPARTAN CAPITAL SECURITIES, LLC
Show Raw Text
CORRESP 1 filename1.htm January 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Virpax Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended File No. 333-284089 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: Monday, January 27, 2025 Requested Time: 5:00 p.m., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, the undersigned, as the sole placement agent for the proposed public offering on a best efforts basis of securities of Virpax Pharmaceuticals, Inc. (the “Company”), hereby join the Company’s request that the effective date of the above-referenced registration statement on Form S-1, as amended, be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on Monday, January 27, 2025, or as soon thereafter as possible. Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, SPARTAN CAPITAL SECURITIES, LLC By: /s/ Kim Monchik Name: Kim Monchik Title: Chief Administrative Officer